Multiple Myeloma (MM): Clinical Trials

7 trials for Multiple Myeloma (MM), newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 not yet recruiting, 2 recruiting, 1 withdrawn. 7 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 37Not yet recruiting 4, Recruiting 2, Withdrawn 1
Phase 22Not yet recruiting 1, Withdrawn 1

Follow Multiple Myeloma (MM): new trials by email Literature Review of Multiple Myeloma (MM) trials Research Report on Multiple Myeloma (MM)

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma
Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide, Bortezomib - Multiple Myeloma (MM)
Phase 2 / Phase 3Not yet recruitingAlliance for Clinical Trials in Oncology9202026-12-232026-10-22
Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma
CM336, CM313, Daratumumab - Multiple Myeloma (MM)
Phase 3Not yet recruitingKeymed Biosciences Co.Ltd3202026-12-012026-11-02
A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease
Teclistamab, Talquetamab, Daratumumab (Subcutaneously) - Multiple Myeloma (MM)
Phase 3Not yet recruitingPolish Myeloma Consortium2482026-09-012026-07-31
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
Daratumumab, Lenalidomide, Dexamethasone - Multiple Myeloma (MM), Plasma Cell Leukemia (PCL)
Phase 3RecruitingUniversity of Leeds12262026-07-032026-11-16
A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)
Linvoseltamab, Bortezomib, Lenalidomide - Multiple Myeloma (MM)
Phase 2 / Phase 3WithdrawnRegeneron Pharmaceuticals2026-06-052026-06-18
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
SCTC21C, Bortezomib, Lenalidomide - Multiple Myeloma (MM)
Phase 3RecruitingSinocelltech Ltd.2922025-12-292026-01-29
Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients
CM336 Injection, Standard Of Care( SOC) - Multiple Myeloma (MM)
Phase 3Not yet recruitingKeymed Biosciences Co.Ltd2802025-09-012025-09-18

Narrower conditions

Multiple Myeloma (7)  ·  Frailty (1)  ·  Leukemia, Plasma Cell (1)  ·  Neoplasm, Residual (1)  ·  Neoplasms, Plasma Cell (1)

Broader conditions

Blood Protein Disorders (7)  ·  Cardiovascular Diseases (7)  ·  Hematologic Diseases (7)  ·  Hemic and Lymphatic Diseases (7)  ·  Hemorrhagic Disorders (7)  ·  Hemostatic Disorders (7)  ·  Immune System Diseases (7)  ·  Immunoproliferative Disorders (7)  ·  Lymphoproliferative Disorders (7)  ·  Neoplasms (7)  ·  Neoplasms by Histologic Type (7)  ·  Paraproteinemias (7)  ·  Vascular Diseases (7)  ·  Neoplasms, Plasma Cell (6)  ·  Pathologic Processes (2)

Interventions

Dexamethasone (5)  ·  Lenalidomide (5)  ·  daratumumab (5)  ·  Bortezomib (3)  ·  talquetamab (3)  ·  Calcium Dobesilate (1)  ·  Focal Adhesion Protein-Tyrosine Kinases (1)  ·  Fumigant 93 (1)  ·  Magnetic Resonance Spectroscopy (1)  ·  Melphalan (1)  ·  Standard of Care (1)  ·  darlin protein, Dictyostelium (1)  ·  pomalidomide (1)

Sponsors

Keymed Biosciences Co.Ltd (2)  ·  Alliance for Clinical Trials in Oncology (1)  ·  Polish Myeloma Consortium (1)  ·  Regeneron Pharmaceuticals (1)  ·  Sinocelltech Ltd. (1)  ·  University of Leeds (1)

Countries

China (3)  ·  United Kingdom (1)

Top investigators

Charlotte Pawlyn (1)  ·  Gang An (1)  ·  Gordon Cook (1)  ·  Hira Shaikh, MBBS (1)  ·  Lugui Qiu (1)  ·  Sarah Holstein, MD, PhD (1)

NIH funding

2025 (2)